Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a guided AI chatbot help women make better screening decisions?

NCT ID NCT07827924

Knowledge-focused Sponsor: Harding Center for Risk Literacy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers are testing whether a specially built AI chatbot can help women make informed decisions about mammography screening. The study compares this guided chatbot with a standard AI chatbot and a standard information brochure. It includes 330 women aged 40 to 70 in the US and UK who speak English as their first language. The main goal is to see if the guided chatbot improves how involved women feel in the decision and whether their choices match their knowledge and values.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
An AI chatbot built to guide shared decision-making about mammography screening, compared with a standard AI chatbot and a standard information brochure
What this could lead to
If the guided chatbot helps, it could give patients a clearer, more personal way to weigh screening choices, especially those who find standard health information hard to follow.
What could go wrong
This is an online experiment with 330 women, not a real clinic visit, so results may not reflect how people decide with their own doctors. The chatbot could still give flawed advice or fail to help.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 330 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 70 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Biological sex: Female. * Age: 40 to 70 years old. * Country of residence: United States (US) or United Kingdom (UK). * Language: Native English speaker (English as first language). * Registered and verified user on the academic research platform Prolific. * Able to read, understand, and provide informed consent digitally. Exclusion Criteria: * Individuals who do not meet the automated pre-screening criteria on the Prolific platform. * Inability to use or access a computer, smartphone, or internet browser required to complete the digital study. Note: Quotas will be enforced during recruitment to ensure a 50/50 stratified split between participants with and without university entrance qualifications to guarantee variance in educational backgrounds. Once a quota is filled, further participants matching that educational profile will be excluded. \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artificial intelligence are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Patient Participation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artificial intelligence Health literacy Patient participation Shared decision making

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.